

FOR IMMEDIATE RELEASE

Contact: Karen Michailo
919-287-4277

Expression Analysis Introduces GWAS Program

Durham, N.C. (April 2, 2008) – Expression Analysis, Inc., the industry’s leading provider of genomic services for clinical trials and research, announced today that it has expanded its services to include a Genome-Wide Association Study (GWAS) program. This new offering will focus on guiding clients through all the details of managing GWAS projects or other large projects ranging from hundreds to thousands of specimens.

“Our GWAS program leverages an exceptional microarray purchasing power to extend cost-effective pricing to all organizations. But most importantly, every project has access to leading microarray platforms as well as our in-depth expertise in array processing and bioinformatics,” stated Steve McPhail, President and CEO of Expression Analysis. “The GWAS program will provide quality services that support regulatory compliance while providing researchers the ability to run many more specimens with much faster turnaround times,” continued McPhail.

The benefits of the program extend further than rapid turn-around and cost-effectiveness; clients will have the assurance their studies will be handled by a proven industry leader with an unmatched depth and breadth of genomic expertise.

For more information about the program visit www.expressionanalysis.com/lvgp.html

About Expression Analysis, Inc.

Expression Analysis, Inc. provides expression profiling and genotyping and sequencing services using Illumina Bead-Chip®, Affymetrix GeneChip® and Applied Biosystems’ TaqMan technologies. As the leading provider of microarray services in clinical trials and research, Expression Analysis offers solutions for challenging specimens such as blood and FFPE tissues, as well as nucleic acid isolation and data analysis services. The organizations CLIA registered lab supports GLP compliance.

— END —

